Oncotelic reports Q3 net loss of $1.9M; provides JV, license, and clinical updates

Oncotelic Therapeutics, Inc.

2022-Q3 EPS reported -$0.03

Net loss: $1.86M (($0.00)/share) vs $1.99M (($0.02)/share) in Q3 2020; operating expenses rose to $1.8M.
Secured $1.5M convertible note from GMP in Sep 2021 plus $0.5M in Oct 2021; JV with GMP for product portfolio at 35% stake.
Exclusive license from Autotelic for patents; milestones up to $50M and 15% royalties on net sales.
OT-101/IL-2 combo safety cohort completed; dose escalation above 140 mg/m² ongoing.
OT-101 COVID-19 trial data locked; showed 4.5% mortality (OT-101) vs 20% placebo and improved overall survival.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.